Why have BMS investors been anything but positive about acquiring 2seventy? The answer stems from uncertainty over how ...
Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...
Shares of 2seventy bio, Inc. (NASDAQ:TSVT – Get Free Report) have received a consensus rating of “Hold” from the eight ...
6d
Fintel on MSNLeerink Partners Downgrades 2seventy bio (TSVT)Fintel reports that on March 11, 2025, Leerink Partners downgraded their outlook for 2seventy bio (NasdaqGS:TSVT) from ...
6d
Pharmaceutical Technology on MSNBMS to acquire longtime cell therapy partner 2seventy bio for $286mThe deal comes after a challenging few years for 2seventy bio, which had divested research programmes in recent years.
The Ademi Firm is investigating 2seventy bio (Nasdaq: TSVT) for possible breaches of fiduciary duty and other violations of ...
Inc. has announced a definitive merger agreement under which BMS will acquire all of the outstanding shares of 2seventy bio.
Morgan Stanley lowered the firm’s price target on 2seventy Bio (TSVT) to $5 from $6 and keeps an Equal Weight rating on the shares following ...
1d
Zacks Investment Research on MSN2seventy bio, Inc. (TSVT) Upgraded to Buy: Here's WhyInc. (TSVT) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the ...
2seventy bio (NASDAQ:TSVT – Get Free Report) had its price objective cut by stock analysts at Morgan Stanley from $6.00 to $5.00 in a research note issued on Friday,Benzinga reports.The firm ...
Cambridge: 2seventy bio, Inc. has announced a definitive merger agreement under which Bristol Myers Squibb will acquire all ...
Investorideas ( ), a go-to platform for big investing ideas for stock traders, including biotech stocks reports on trading and news for 2seventy bio ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results